hVIVO were contracted by a US-based clinical-stage biopharmaceutical company to conduct an Influenza Phase IIa challenge study with their investigational product. Their lead candidate was a first-in-class, broadly neutralising anti-influenza A and B therapeutic comprised of fully human polyclonal antibodies designed to prevent and treat human influenza infections.
